Thousands of Actos Lawsuits Expected

Thousands of Actos  lawsuits are expected to be filed in the near future. In fact, Actos cancer lawyers estimate that the number could top 15,000 - and include allegations of fraud, failure to warn and more.

Takeda & Eli Lilly May Have Known About Actos Bladder Cancer Risks

Hundreds of Actos bladder cancer lawsuits have already been filed against manufacturers Takeda Pharmaceuticals and drug giant Eli Lilly. Actos attorneys allege that Takeda and Lilly either knew or should have known about these risks, but failed to warn the public. They point to studies conducted in the 1990s - before the drug was even approved - showing increased urinary bladder tumors in male rats.

In addition, a 2005 study called "PROactive" sponsored by the manufacturers showed a higher percentage of bladder cancer cases in patients who received Actos versus similar drugs. Unfortunately, the results of that study were never published - resulting in more Actos users developing unnecessary bladder cancer.

One thing is clear, it's the responsibility of drug companies to confirm the safety of the drugs they're placing on the market. As more and more Actos bladder injury cases are filed, additional information about what the company knew about these risks - and when it knew it - will surface. For now, the U.S. Food & Drug Administration (FDA) has forced the company to act.

FDA Actos Warning

The FDA required Takeda to change the label on Actos in July of 2011 after a French study showed an increased risk of bladder cancer within only 12 months of using the drug - and certainly after 24 months of use. That study looked at nearly 1.5 million diabetics - 155,000 of whom took Actos and the remaining 1.3 million who took other diabetes drugs. It revealed that Actos patients were at a 22 percent higher risk of developing bladder cancer than patients on other medications. That study caused both France and Germany to pull the drug off of shelves.

What's disturbing, according to Actos injury attorneys, is that the company didn't use that information to warn consumers in other countries - including the United States. It took FDA action to force the company to react.

Who's Responsible for Actos Bladder Injuries?

Many consumers think that the FDA does its own studies evaluating the risks with a pharmaceutical product before approving a drug to be sold on the U.S. market. However, that simply isn't true. The FDA actually has little involvement with the studies that are conducted and leaves that responsibility almost entirely to the pharmaceutical company that placed that drug on the market to prove that it's safe.

There's a definite disconnect between what the FDA does and what the public believes it does. In this situation, Takeda and Lilly should have conducted their own studies, looked into the association between Actos and bladder cancer, determined the risk - and then provided fair and adequate warning to those who were taking the drug. They failed to do that in a timely manner.

The bottom line is that pharmaceutical companies have a responsibility to consumers to protect them from these types of adverse events or - at the very least - provide them with all the information they can about these risks so that consumers and physicians can make an informed decision about possible alternative treatment options.

When they fail to satisfy the obligations and duties they owe to consumers, they must be held accountable for their conduct. If you've been injured, contact an Actos injury lawyer to see if you might be entitled to compensation   for medical bills, lost wages, pain and suffering and more.